Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent
AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an...To view the full article, register now.
Already a subscriber? Click here to view full article